Global and China Biopharmaceutical Industry Report, 2010
  • Sep/2010
  • Hard Copy
  • USD $1,900
  • Pages:121
  • Single User License
    (PDF Unprintable)       
  • USD $2,000
  • Code: YF005
  • Enterprise-wide License
    (PDF Printable & Editable)       
  • USD $3,000
  • Hard Copy + Single User License
  • USD $2,100
In recent years, biopharmaceutical industry has been the fastest growing sector in the global pharmaceutical industry. From 1998 to 2009, the compound annual growth rate of biopharmaceutical industry reached 18.6%, far higher than 8.5% of the global pharmaceutical market. USA is the most active country in R & D and innovation of biopharmaceutical products, taking the core position in the global biotechnology industry. Now, nearly 60% of biotechnology patents are held by USA.

At present, there are more than 700 companies in China’s biological and bio-chemical pharmaceutical industry, with total sales revenue of about RMB75.3 billion in 2009. Growing at a compound annual growth rate of about 30% from 2005 to 2009, China biological and bio-chemical pharmaceutical industry had become one of the fastest growing fields in China pharmaceutical industry. China is still backward in biomedical development compared with European and American countries. Currently, China biological and bio-chemical pharmaceutical industry only takes a small proportion in China pharmaceutical industry, and only contributed 10% to the total sales revenue in 2009, so it has broad room for growth.

Sales Revenue and YoY Growth Rate of China Biological and Bio-chemical Pharmaceutical Industry, 2005-2009
Source: ResearchInChina

As for segments, the international blood products market is monopolized by big companies, Bayer and Baxter acquire as high as 80% market shares. Due to the lack of plasma, China is confronted with tight supply of blood products, with low concentration degree and many manufacturers. In the international blood products market, coagulation factor products take the dominating position; however, in the Chinese blood products market, human albumin and immune globulin products take the dominating position, while coagulation factor products account for a small proportion and have huge potentials in the future. Hualan and Shanghai RAAS have diversified blood products with strong competitiveness.

Hualan’s Operating Income (by Product), 2007-2009 (Unit: RMB mln)
Source: ResearchInChina

Hualan’s Gross Margin (by Product), 2007-2009
Source: ResearchInChina

The international vaccine market has high concentration degree. GlaxoSmithKline, Sanofi-Aventis, Merck, Pfizer/Wyeth and Novartis are the leaders in the market. Chinese vaccine market has low concentration degree, with many manufacturers. Vaccine I (planned vaccine) still has potentials because of the big difference between China and high-income countries in child mortality; Vaccine II has huge potentials in the future with the rise of per capita income and the enhancement of citizens’ awareness of disease prevention. Tiantan Biological has many types of vaccine, and it has acquired Chengdu Ronsen which has one of the largest blood product workshops, so it will achieve growth in the future.

In the international diagnostic reagent market, mergers and acquisitions frequently occur. The pharmaceutical giants are aggressively acquiring small and medium diagnostic reagent companies. Increased product lines and expanded application fields make diagnostic reagent grow rapidly. In Chinese diagnostic reagent market, the major companies include KHB, Da An Gene and so on. The low-end biochemical diagnostic reagents occupy the leading position in Chinese market, but China is developing mainstream immune diagnostic reagents and nucleic acid diagnostic reagents which are popular in the international market.

Monoclonal antibody drugs have been the antibody drugs with the highest compound annual growth rate in recent years. Among Top 20 Best-Selling Drugs in the World in 2009, there were four monoclonal antibody drugs. During 1999 to 2009, the compound growth rate of the global monoclonal antibody drug market reached 62.88%. Chinese monoclonal antibody drug market is still in the initial stage, and the market only values RMB1 billion, showing a big gap with the developed countries in Europe and the United States. Now, China has had antibody drug industrial bases in Beijing, Shanghai and Xi'an. The base in Beijing is led by Beijing Biotech Pharmaceutical Co., Ltd. (BPL) and Beijing Mabworks Biotech Co., Ltd. The base in Shanghai is led by Shanghai CP Guojian Pharmaceutical Co., Ltd. (CPGJ). The base in Xi'an is led by the Fourth Military Medical University and Chengdu Huasun Group.

Recombinant protein drugs are widely used in the treatment of a variety of major diseases, with huge market potentials. GeneScience Pharmaceuticals Co., Ltd. (GenSci) which is a subsidiary of Changchun High and New Technology Industries (Group) Inc. is the first one to develop recombinant human growth hormone in China, with large market shares. Anke Biotechnology is the only manufacturer that is granted with the approval to produce interferon and growth hormone at the same time. Tonghua Dongbao is a leading enterprise in China insulin industry, and long-acting insulin will be the highlight in its future growth. Therapeutic antibodies and genetic engineering vaccines will generate considerable revenue for SL Pharmaceutical.
1. Overview of Biopharmaceutical Industry
1.1 Introduction
1.2 Main Products

2. Overview of Global Biopharmaceutical Industry
2.1 Development
2.2 USA
2.3 Europe
2.4 Japan

3. Status Quo of China Biopharmaceutical Industry
3.1 Rapid Growth
3.2 Policy Support

4. Key Segment Markets of Biopharmaceutical Industry
4.1 Blood Products
4.1.1 Concept
4.1.2 Global Market
4.1.3 Chinese Market
4.2 Vaccine
4.2.1 Characteristics and Classification
4.2.2 Development in the World
4.2.3 Development in China
4.3 Diagnostic Reagents
4.4 Monoclonal Antibodies
4.4.1 Profile
4.4.2 Development in the World
4.4.3 Development in China
4.5 Recombinant Protein Drugs
4.5.1 Interferon
4.5.2 Growth Hormone
4.5.3 Recombinant Human Insulin
4.5.4 Recombinant Human Follicle-stimulating Hormone
4.5.5 Long-acting Recombinant Protein Drugs

5. Chinese Enterprises
5.1 Hualan Biological Engineering
5.1.1 Profile
5.1.2 Operation
5.2 Shanghai RAAS   
5.2.1 Profile
5.2.2 Operation
5.2.3 Strategy
5.3 KHB 
5.3.1 Profile
5.3.2 Operation
5.3.3 Strategy
5.4 Da An Gene    
5.4.1 Profile
5.4.2 Operation
5.4.3 Strategy
5.5 Tiantan Biological   
5.5.1 Profile
5.5.2 Operation
5.5.3 Strategy
5.6 SL Pharmaceutical  
5.6.1 Profile
5.6.2 Operation
5.6.3 Strategy
5.7 Changchun High and New Technology
5.7.1 Profile
5.7.2 Operation
5.7.3 Strategy
5.8 Anke Biotechnology  
5.8.1 Profile
5.8.2 Operation
5.8.3 Strategy
5.9 Tonghua Dongbao  
5.9.1 Profile
5.9.2 Operation
5.9.3 Strategy
5.10 Sino Biopharmaceutical Limited
5.10.1 Profile
5.10.2 Operation
5.11 Other Companies
5.11.1 BPL  
5.11.2 CPGJ 
5.11.3 Wantai Biological Pharmacy   
5.11.4 Livzon
5.11.5 Sichuan Shuyang 

6. International Biopharmaceutical Companies
6.1 GlaxoSmithKline
6.1.1 Profile
6.1.2 Operation
6.1.3 GlaxoSmithKline (China)
6.2 Roche
6.2.1 Profile
6.2.2 Operation
6.2.3 Shanghai Roche 
6.3 Amgen
6.3.1 Profile
6.3.2 Operation
6.4 Novo Nordisk
6.4.1 Profile
6.4.2 Operation
6.4.3 Novo Nordisk (China)
6.5 Merck
6.5.1 Profile
6.5.2 Operation
6.6 Novartis
6.6.1 Profile
6.6.2 Operation
6.6.3 China Novartis Institute for BioMedical Research
6.7 Sanofi-Aventis
6.7.1 Profile
6.7.2 Operation
6.7.3 Operation in China
6.8 AstraZeneca
6.8.1 Profile
6.8.2 Operation
6.8.3 AstraZeneca (China)
6.9 Bristol-Myers Squibb
6.9.1 Profile
6.9.2 Operation
6.9.3 Bristol-Myers Squibb (China)
6.10 Eli Lilly
6.10.1 Profile
6.10.2 Operation
6.10.3 Operation in China
6.11 Johnson & Johnson
6.11.1 Profile
6.11.2 Operation
6.11.3 Operation in China
Major Types of Biological Products
Global Biopharmaceutical Market Scale and YoY Growth Rate, 2000-2009
Proportion of Global Biopharmaceutical Income (by Region), 2008
Proportion of Global Biopharmaceutical R & D Expenses (by Region), 2008
R&D Investment of Leading Biopharmaceutical Enterprises in the World, 2008
"Blockbusters" in Global Biopharmaceutical Industry, 2009
Types of Biotechnology Drugs in Clinical Trials in USA, 2008
Sales Revenue and YoY Growth Rate of China Biological and Bio-chemical Pharmaceutical Industry, 2005-2009
Sales Proportion of Chinese Pharmaceutical Manufacturing Sub-sectors, 2009
Proportion of Blood Products in Global Market (by Product), 2009
Proportion of Blood Products in Chinese Market (by Product), 2008
Proportion of Chinese Blood Products Manufacturers, 2006
Major Manufacturers and Their Shares in Chinese Human Albumin Market, 2009
Major Manufacturers and Their Shares in Chinese Intravenous Human Immunoglobulin Market, 2009
Major Manufacturers and Their Shares in Chinese Human Coagulation Factor VIII Market, 2009
Major Manufacturers and Their Shares in Chinese Human Prothrombin Complex Market, 2009
Sales Revenue and YoY Growth Rate of Global Vaccine Market, 2005-2009
Vaccine Sales Revenue of Major Vaccine Manufacturers in the World, 2006-2009
Major Manufacturers and Their Shares in Global Vaccine Market, 2009
Prevention Sector and Share in Global Vaccine Industry
Sales Revenue of Blockbuster Vaccine Products in the World, 2006-2009
Sales Revenue of Vaccines in China, 2006-2009
Lot Release of H1N1 Influenza Vaccines of All Companies in China, 2009
Major Manufacturers and Their Shares in Chinese Influenza Split Vaccine Market (by Lot Release), 2009
Lot Release of Varicella Vaccines, 2009 & Jan-Apr 2010 
Major Manufacturers and Their Shares in Chinese Varicella Vaccine Market (by Lot Release), 2009
M & A Cases in Global Diagnostic Reagent industry, Jan 2007-Jan 2010
Major Diagnostic Reagent Manufacturers in China
Categories of Diagnostic Reagents in China by Proportion, 2009
Comparison between Monoclonal Antibody Drugs and Traditional Drugs (for cancer)
Sales Revenue and YoY Growth Rate of Global Monoclonal Antibodies, 1999-2009
Classification of Recombinant Protein Drugs
Recombinant Protein Drugs by Product and Share, 2009
Global Interferon market Scale, 2003-2009
Chinese Interferon market Scale, 2004-2008
Major Manufacturers and Their Shares in Chinese Interferon Market, 2009
Global Growth Hormone Market Scale and YoY Growth Rate, 2003-2008
Chinese Growth Hormone Market Scale and YoY Growth Rate, 2004-2008
Major Manufacturers and Their Shares in Chinese Growth Hormone Market, 2009
Hospital Terminal Scale and Growth Rate of Chinese recombinant insulin, 2004-2009
Major Manufacturers and Their Shares in Chinese Insulin Market, 2009
Major Manufacturers and Their Shares in Chinese Follicle-stimulating Hormone Market, 2009
Sales Revenue of Major Long-acting Recombinant Protein Drugs in the World, 2009
Hualan’s Operating Income and Net Profit, 2006-1Q2010
Hualan’s Operating Income (by Industry), 2007-2009
Hualan’s Operating Income (by Product), 2007-2009 
Hualan’s Operating Income (by Region), 2007-2009
Hualan’s Gross Margin (by Product), 2007-2009
Production of Blood Products Manufacturers in China, 2009
Operating Income and Net Profit of Shanghai RAAS, 2006-1Q2010
Lot Release of Biological Products of Shanghai RAAS, 2009
Operating Income of Shanghai RAAS (by Product), 2005-2009
Gross Margin of Shanghai RAAS (by Product), 2005-2009
Plasma Volume of Shanghai RAAS, 2007-2011E
Operating Income of Shanghai RAAS (by Region), 2008-2009 
Comparison between Gene Recombinant Blood Products and Traditional Blood Products 
KHB’s Operating Income and Net Profit, 2006-1Q2010
KHB’s Operating Income (by Product), 2007-2009
Sales Revenue of KHB’s Diagnostic Reagents (by Product), 2007-2009
Forecast for KHB’s Income from Blood Screening Business
Operating Income and Net Profit of Da An Gene, 2006-1Q2010
Operating Income of Da An Gene (by Product), 2007-2009
Operating Income and YoY Growth Rate of Nucleic Acid Diagnostic Reagents of Da An Gene, 2004-2008
Forecast for Income of Da An Gene from Blood Screening Business
Operating Income and Net Profit of Tiantan Biological, 2006-1Q2010
Operating Income of Tiantan Biological (by Product), 2007-2009
Gross Margin of Tiantan Biological (by Product), 2007-2009
Operating Income of Tiantan Biological (by Region), 2007-2009
Operating Income and Net Profit of SL Pharmaceutical, 2006-1Q2010
Proportion of R & D Cost to Operating Income of SL Pharmaceutical, 2007-2009
Operating Income of SL Pharmaceutical (by Region), 2007-2009
Operating Income and Net Profit of Changchun High and New Technology, 2006-2Q2010
Operating Income of Changchun High and New Technology (by Industry), 2007-1H2010
Operating Income of Changchun High and New Technology (by Region), 2007-2009
GenSci’s Sales Revenue and Net Profit, 2003-2009
GenSci’s Upcoming New Drugs, 2010
Operating Income and Net Profit of Anke Biotechnology, 2006-1Q2010   
Operating Income of Anke Biotechnology (by Product), 2006-2009
Operating Income of Major Biological Products of Anke Biotechnology, 2006-2009
Operating Income and Net Profit of Tonghua Dongbao, 2007-2Q2010
Prime Operating Income of Tonghua Dongbao (by Product), 2007-2009
Gross Margin of Tonghua Dongbao by Product, 2007-2009
Operating Income of Tonghua Dongbao (by Region), 2007-2009
Operating Income and Gross Profit of Sino Biopharmaceutical, 2007-2Q2010
Operating Income of Sino Biopharmaceutical (by Product), 2007-2009
CPGJ’s Sales Revenue from Etanercept, 2006-2009
GlaxoSmithKline’s Operating Income and Operating Profit, 2006-1Q2010
GlaxoSmithKline’s Income in All Therapeutic Sectors, 2007-2009
GlaxoSmithKline’s Income (by Region), 2007-2009
Operating Income and Operating Profit of Shanghai GlaxoSmithKline, 2007-2008
Roche’s Sales Revenue and Net Profit, 2007-1H2010
Roche’s Sales Revenue (by Industry), 2007-2009
Roche‘s Sales Revenue in Pharmaceutical Industry (by Sector), 2007-2009
Roche‘s Sales Revenue in Pharmaceutical Industry (by Region), 2008-2009
Roche’s Sales Revenue from Diagnostic Reagents, 2002-2009
Roche’s Income Structure in Diagnostics Sector (by Product), 2007-2009
Roche’s Income Structure in Diagnostics Sector (by Region), 2007-2009
Roche’s Sales Revenue from Four Monoclonal Antibody Drugs, 2006-2009
Operating Income and Operating Profit of Shanghai Roche, 2007-2008
Amgen’s Operating Income and Net Profit, 2006-2009
Amgen’s Operating Income (by Product), 2007-2009
Sales Revenue and Net Profit of Novo Nordisk, 2005-1H2010
Sales Revenue of Novo Nordisk (by Industry), 2005-2009
Sales Revenue (by Product) in Diabetes Sector, 2005-2009
Sales Revenue (by Product) in Biopharmaceutical Sector, 2005-2009
Sales Revenue of Novo Nordisk (by Region), 2005-2009
Operating Income and Operating Profit of Novo Nordisk (China), 2007-2008
Merck’s Sales Revenue and Net Profit, 2007-2009
Merck’s Income (by Region), 2007-2009
Income and YoY Growth Rate of Merck’s Vaccine Products, 2002-2008
Novartis’s Net Sales Revenue and Net Profit, 2007-2009
Novartis’s Net Sales Revenue (by Industry), 2008-2009
Novartis’s Net Sales Revenue (by Region), 2007-2009
Net Sales Revenue and Net Profit of Sanofi-Aventis, 2007-1H2010
Sales Revenue of Human Vaccines of Sanofi-Aventis, 2009
Operating Income and Operating Profit of Hangzhou Sanofi-Aventis Minsheng Pharmaceutical, 2007-2008
Operating Income and Operating Profit of Shenzhen Sanofi Pasteur, 2007-2008
Operating Income and Operating Profit of Sanofi-Aventis (Beijing), 2007-2008
AstraZeneca’s Sales Revenue and Operating Profit, 2007- H1 2010
AstraZeneca’s Sales Revenue (by Sector), 2007-2009
AstraZeneca’s Sales Revenue (by Region), 2007-2009
AstraZeneca’s Sales Revenue in North America (by Region), 2007-2009
AstraZeneca’s Sales Revenue in Other Markets (by Region), 2007-2009
AstraZeneca’s Sales Revenue in Emerging Markets (by Region), 2007-2009
AstraZeneca’s Operating Income and Operating Profit in China, 2007-2008
Net Sales Revenue, Net Biopharmaceutical Sales Revenue and Its Proportion of Bristol-Myers Squibb, 2007-2009
Net Sales Revenue of Main Products of Bristol-Myers Squibb, 2007-2009
Net Sales Revenue of Bristol-Myers Squibb (by Region), 2007-2009
Operating Income and Operating Profit of Sino-American Shanghai Squibb, 2007-2008
Operating Income and Net Profit of Eli Lilly, 2006-1H2010
Operating Income of Main Products of Eli Lilly, 2007-2009
Operating Income and Operating Profit of Eli Lilly (Suzhou), 2007-2008
Operating Income and Net Profit of Johnson & Johnson, 2006-2009
Operating Income of Johnson & Johnson (by Industry), 2007-2009
Operating Income of Johnson & Johnson (by Region), 2007-2009
Operating Income and Operating Profit of Xi’an-Janssen, 2007-2008

Global and China DNA Sequencing Industry Research Report, 2014-2017

DNA sequencing is the process of reading nucleotide bases in a specific DNA molecule, that is to say determining the arrangement mode of adenine, thymine, cytosine, and guanine. It can be applied in a...

Global and China Stem Cell Industry Report, 2014-2017

Stem cells are undifferentiated biological cells that can differentiate into specialized cells and can divide (through mitosis) to produce more stem cells. Stem cell therapy can be applied to treatmen...

China Human Vaccine Industry Report, 2014-2017

Vaccines can prevent and control infectious diseases, so the demand for these biological products is relatively rigid. In 2013, China’s human vaccine lot release volume grew by 4.9% from a year earlie...

China Blood Product Industry Report, 2014-2017

Plasma resource reserves and control are crucial to the development of blood products industry. Although the closure of 16 plasma collection stations in Guizhou in 2011 didn’t cause major disruption t...

China Animal Vaccine Industry Report, 2013-2016

Animal vaccine is a kind of biological agent that enables inoculated animals to produce active immunity for disease prevention. Europe and the United States and other developed countries are the main ...

China Contract Research Organization (CRO) Industry Report, 2013-2016

China CRO industry has developed rapidly in recent years, registering a CAGR of 27.2% during 2007-2013, of which the market size reached RMB 36 billion in 2013, occupying 10% of global market share. ...

Global and China Biodegradable Plastics Industry Report, 2013-2016

Global biodegradable plastic production and demand have grown rapidly in recent years, and the capacity reached 1-1.5 million t/a in 2012-2013. Among dozens of biodegradable plastic varieties develope...

Global and China Industrial Enzyme Industry Report, 2014-2016

In 2007-2013, the global industrial enzyme market size grew at the CAGR of 5.7%, reaching USD4.04 billion in 2013, 1.4 times that in 2007. The global industrial enzyme market is monopolized by a small...

China Heparin Industry Report, 2013-2015

Since the small intestines of pigs (raw materials for production of heparin) in China are abundant (the pig slaughtering volume in China approximates 50% of globe’s total) and heparin APIs are gradual...

China Lactic Acid and Derivative Industry Report, 2013

China’s lactic acid capacity and output continued to grow at the respective CAGR of 22.7% and 28.7% in 2007-2011. But limited by market demand, the annual output of most vendors was below their design...

China Human Vaccine Industry Report, 2012-2015

In the wake of China's economic growth and enhanced disease prevention awareness, Chinese human vaccine market has been expanding. In 2012, Chinese human vaccine market valued RMB10.5 billion with the...

China Blood Product Industry Report, 2012-2015

Plasma is a key raw material of the blood product industry. In August 2011, China shut down 16 plasma stations in Guizhou, resulting in a decrease of 15% in the plasma volume of the year. However, due...

China Animal Vaccine Industry Report, 2012-2015

In view of the frequent occurrence of animal epidemic diseases over the years, the Chinese government has increased investment in epidemic prevention and implemented compulsory immunization system. Be...

Global and China Monoclonal Antibody Industry Report, 2013

In recent years, the monoclonal antibody market around the globe has witnessed substantial growth, and the CAGR of market scale during 1997-2011 has reached 44% approximately. It is predicted that the...

China Insulin Industry Report, 2012-2015

China is a country with the largest number of diabetics. In 2011, the market scale of diabetes medicine in China approximated RMB13.8 billion, of which, insulin medicines mainly comprising recombinant...

China Heparin Industry Report, 2012-2014

China, abundant in heparin raw materials, has become one of the world’s largest heparin API producers and exporters, owning to the quality of heparin API having won international recognition gradually...

Global and China Industrial Enzyme Industry Report, 2012-2014

Industrial enzyme which refers to the enzyme preparation used for industrial purposes can be applied to detergent, animal feed, bread, brewing (beer, wine, etc.), papermaking, textile, bio-ethanol and...

China Blood Products Industry Report, 2011-2012

Blood plasma serves as key raw material in blood product industry. In August 2011, the shut-down of 16 plasma collection stations in Guizhou province, China resulted in a YoY decline of 15% in plasma ...

2005-2014 All Rights Reserved 京ICP备05069564号-1 京公网安备1101054484号